Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth
详细信息 查看全文
- 作者：Jun Dong (1)
Guanghua Zhou (1)
Dongfang Tang (1)
Yanming Chen (1)
Baoqian Cui (1)
Xingliang Dai (1)
Jinshi Zhang (1)
Qing Lan (1)
Qiang Huang (1) - 关键词：Glioma ; Temozolomide ; Slow ; releasing microsphere ; Interstitial chemotherapy
- 刊名：Journal of Cancer Research and Clinical Oncology
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：138
- 期：12
- 页码：2079-2084
- 全文大小：365KB
- 参考文献：1. Banissi C, Ghiringhelli F, Chen L, Carpentier AF (2009) Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 58(10):1627-634 CrossRef
2. Dong J, Zhang Q, Huang Q, Chen H, Shen Y, Fei X et al (2010) Glioma stem cells involved in tumor tissue remodeling in a xenograft model. J Neurosurg 113(2):249-60 CrossRef
3. Fei XF, Zhang QB, Dong J, Diao Y, Wang ZM, Li RJ et al (2010) Development of clinically relevant orthotopic xenograft mouse model of metastatic lung cancer and glioblastoma through surgical tumor tissues injection with trocar. J Exp Clin Cancer Res 29:84 CrossRef
4. Fleming AB, Saltzman WM (2002) Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 41(6):403-19 CrossRef
5. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K (2011) Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev 3:CD007294
6. Holdhoff M, Grossman SA (2011) Controversies in the adjuvant therapy of high-grade gliomas. Oncologist 16(3):351-58 CrossRef
7. Li XN, Du ZW, Huang Q, Wu JQ (1997) Growth-inhibitory and differentiation-inducing activity of dimethylformamide in cultured human malignant glioma cells. Neurosurgery 40(6):1250-258 (discussion 1258-259) CrossRef
8. Tomayko MM, Reynold CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148-54 CrossRef
9. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O et al (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41(1):44-8 (discussion 48-9) CrossRef
10. Whittle IR, Lyles S, Walker M (2003) Gliadel therapy given for first resection of malignant glioma: a single centre study of the potential use of Gliadel. Br J Neurosurg 17(4):352-54 CrossRef
11. Zhang H, Gao S (2007) Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. Int J Pharm 329(1):122-28 CrossRef - 作者单位：Jun Dong (1)
Guanghua Zhou (1)
Dongfang Tang (1)
Yanming Chen (1)
Baoqian Cui (1)
Xingliang Dai (1)
Jinshi Zhang (1)
Qing Lan (1)
Qiang Huang (1)
1. Department of Neurosurgery, 2nd Affiliated Hospital of Suzhou University, Suzhou, 215004, China - ISSN：1432-1335
文摘
Background Currently, treatment of malignant gliomas with temozolomide in addition to surgical resection and radiotherapy remains the foundation of glioma therapy. In an effort to develop new therapeutic choices to treat malignant gliomas, we have designed slow-releasing microspheres that deliver temozolomide (P-TMZ). The local continuous release of temozolomide at the intracranial tumor site may overcome many obstacles associated with systemic delivery, which will help to further improving the therapeutic effects against malignant gliomas. Methods Slow-releasing microspheres containing 10?% temozolomide were prepared, the antitumor efficacy in vitro was evaluated with MTT assay, and the therapeutic efficacy in vivo against gliomas was assessed in human glioma (SGH44) nude mice s.c. and orthotopic xenograft models. Results A single local injection of P-TMZ led to significant reduction both in s.c. and orthotopic human SHG44 glioma xenografts. P-TMZ, BCNU and TMZ had significant antiglioma effect (P?<?0.01), their IC50 value was all less than 10?μg/ml. Tumor inhibition ratio of P-TMZ, BCNU and TMZ in vivo was higher than empty microspheres P0 (P?<?0.01); P-TMZ and BCNU showed higher antitumor efficacy than TMZ (P?<?0.05). Conclusions Our present results suggest that local delivery of slow-releasing temozolomide microspheres is effective for malignant gliomas. P-TMZ retained good antitumor activity and had better therapeutic effect against glioma both in vitro and in vivo, which provide a new choice for future clinical interstitial chemotherapy.